Effect of indacaterol/glycopyrronium (IND/GLY) vs salmeterol/fluticasone (SFC) on moderate or severe COPD exacerbations and lung function based on baseline blood eosinophil counts: Results from the FLAME study
Kenneth R. Chapman (Toronto, Canada), Kenneth R. Chapman, Claus F. Vogelmeier, Angel FowlerTaylor, Tim Ayers, Chau Thach, Anupama Shrinivasan, Robert Fogel, Francesco Patalano, Donald Banerji
|  |
Effect of different inhalation methods on the airway clearance in moderate and severe AECOPD
Hongjing Lin (Changchun City, China), Hongjing Lin, Xin Zhong, Zeyu Qin, Xueli Zhang, Jiahui Ma
|  |
Tiotropium in chronic obstructive pulmonary disease: Gender differences in outcomes
Robert A Wise (Baltimore, United States of America), Robert A. Wise, Antonio Anzueto, Achim Mueller, Norbert Metzdorf, Peter M.A. Calverley
| |
Long term treatment with n-acetylcysteine reduces exacerbations in moderate chronic obstructive pulmonary disease
Alberto Papi (Ferrarra, Italy), Alberto Papi, Gerard Criner, Guy Brusselle, Peter Calverley, Jinping Zheng, Francesco Sergio, Paolo Morelli, Leonardo Fabbri, Nanshan Zhong
| |
The healthcare burden of non-compliance to pharmacotherapeutic escalation recommendations for COPD
Ruben Tavares (Mississauga, Canada), Ruben Tavares, William Zhang, Tam Dang-Tan, Afisi Ismaila, Melissa Stutz, Natalie Coletta, Julie Vaillancourt, Daria Parsons, Xiwu Lin, Gilbert Nadeau, Alexander Simidchiev, John Sampalis
| |
Reduction in clinically important deterioration in COPD with aclidinium/formoterol
Dave Singh (Manchester, United Kingdom), Dave Singh, Anthony D. D’Urzo, Ferran Chuecos, Anna Muñoz, Esther Garcia Gil
| |
Identification of factors associated with exacerbation risk in severe COPD: Multivariate analysis of the WISDOM study
Claus Vogelmeier (Marburg, Germany), Claus Vogelmeier, Leonardo M. Fabbri, Susan Bell, Kay Tetzlaff, Helgo Magnussen, Henrik Watz
| |
Effect of low dose theophylline as adjunct in treatment of COPD
Mrityunjaya Singh (Varanasi, India), Mrityunjaya Singh, Sudhir Kumar Agarwal, Manoj Meena, Shruti Singh
| |
Long-term outcome following first clinically important deterioration in COPD
Ian Naya (Uxbridge , United Kingdom), Ian Naya, Lee Tombs, Hana Mullerova, Chris Compton, Paul Jones
| |
Mepolizumab in COPD with eosinophilic bronchitis: A randomized clinical trial
Angira Dasgupta (Kolkata, India), Angira Dasgupta, Melanie Kjarsgaard, Dante Capaldi, Katherine Radford, Fernando Aleman, Grace Parraga, Len Altman, Thomas Wight, Paul M. O’Byrne, Parameswaran Nair
| |
Inhaled treatment of COPD: A delphi consensus statement
Vincent Ninane (Bruxelles, Belgium), Vincent Ninane, Jean-Louis Corhay, Paul Germonpré, Wim Janssens, Guy Joos, Giuseppe Liistro, Walter Vincken, An Lehouck
| |
Rate of FEV1 decline by FEV1 percent predicted in UPLIFT® and TIOSPIR®
Michael B Drummond (Baltimore, United States of America), Michael B. Drummond, Donald P. Tashkin, Antonio Anzueto, Christoph Hallmann, Achim Mueller, Norbert Metzdorf, Ulrika Hinkel, Robert A. Wise
| |
Tolerability of different dosing regimens of roflumilast in severe COPD (OPTIMIZE)
Henrik Watz (Grosshansdorf, Germany), Henrik Watz, Nitin Bagul, Ken Nip, Rui Sun, Udo-Michael Goehring, Peter Calverley, Klaus Rabe
| |
Benefit of FDC budesonide (BUD) and formoterol fumarate (FF) FDC delivered by a novel MDI co-suspension technology (BFF MDI), in patients (pts) with moderate-to-severe COPD
Edward Kerwin (Medford, United States of America), Edward Kerwin, Thomas Siler, Samir Arora, Patrick Darken, Chad Orevillo, Earl St. Rose, Colin Reisner
| |
Beneficial effect of the LAMA/LABA glycopyrronium (GP)/formoterol (FF) fixed-dose combination, delivered using a novel MDI co-suspension technology (GFF MDI), in COPD GOLD group A and B patients
Leonardo Michele Fabbri (Modena, Italy), Leonardo Michele Fabbri, Fernando Martinez, Klaus F. Rabe, Roberto Rodriguez-Roisin, Gary T. Ferguson, Paul Jones, Stephen Rennard, Shahid Siddiqui, Chad Orevillo, Patrick Darken, Colin Reisner
| |
Cardiovascular (CV) safety of indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone combination (SFC) in moderate-to-very severe COPD patients with prior exacerbations: The FLAME study
Petter Olsson (Alvsjo, Sweden), Petter Olsson, Nicolas Roche, Jørgen Vestbo, Angel FowlerTaylor, Tim Ayers, Chau Thach, Karyn Clerkin, Robert Fogel, Francesco Patalano, Donald Banerji
| |
Treatment effect of umeclidinium/vilanterol and tiotropium on SGRQ sub-domains
John Riley (Uxbridge, United Kingdom), John Riley, Lee Tombs, Mitra Vahdati-Bolouri, Margaret Tabberer, Paul Jones
| |
Drug particle size and lung deposition in COPD
Martyn Biddiscombe (London, United Kingdom), Martyn Biddiscombe, Sally Meah, Peter Barnes, Omar Usmani
| |